Figure 1 Suppression of SLC22A3 and A-to-I editing

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 2 Exosome composition

promotes the oncogenic activity of CagA

Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Patients cured of HCV infection

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 1 Gut microorganisms at the intersection of several diseases

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Figure 4 Tumour-induced neutrophil extracellular trap

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 HCV life cycle and site of action of DAAs

Figure 6 Combination therapy for HCC

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Exosomes with siRNAs targeting

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Pseudorelaxation as a consequence of

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Median coverage and distribution by

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 4 Diverse molecular mechanisms of long non-coding RNAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The role of CTLA4 and PD1 in T cell activation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 High-resolution manometry studies performed

Figure 1 Animal models of liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Figure 1 Structure and composition of the brush border

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Bile acid-induced hepatic inflammation and carcinogenesis

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

2DG suppresses of lamellipodia and filopodia and causes disorganization of F-actin filaments in murine endothelial cells. 2DG suppresses of lamellipodia.

Figure 1 The spread of colorectal cancer metastases

Functions of selected IFN-inducible proteins.

Presentation transcript:

Figure 1 Suppression of SLC22A3 and A-to-I editing of SLC22A3 mRNA by ADAR2 promotes early onset and progression of familial ESCC Figure 1 | Suppression of SLC22A3 and A-to-I editing of SLC22A3 mRNA by ADAR2 promotes early onset and progression of familial ESCC. a | Unedited solute carrier family 22 member 3 (SLC22A3) inhibits the metastasis-promoting function of α-actin 4 (ACTN4). b | In patients with familial oesophageal squamous cell carcinoma (ESCC) with absence or reduced expression of unedited SLC22A3, ACTN4 crosslinks actin filaments and coverts them into actin bundles, promoting filopodia formation and metastasis. c | The edited SLC22A3 isoform is unable to interact with ACTN4 and also promotes filopodia formation and metastasis. ADAR2, adenosine deaminase acting on RNA 2 (also known as ADARB1); D, aspartate; N, asparagine. Nishikura, K. (2017) RNA editing of SLC22A3 mRNAs: causative relevance to familial ESCC? Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.102